EUVIMEDEUVIMED entdecken
VergleichsstudieKohortenstudieOpen Access · CC BY-NC-ND 4.0

Comparative effectiveness and safety of enzalutamide versus abiraterone in patients with metastatic castration-resistant prostate cancer: a nationwide registry-based cohort study from Taiwan

Wen-Kuan Huang, Po-Jung Su, Chun-Chi Chen, Ching-Fu Chang, Shao-Ming Yu, Ming-Jer Hsieh, Ming-Lung Tsai, Tien-Hsing Chen, Pao-Hsien Chu, I-Chang Hsieh, See-Tong Pang, Dong-Yi Chen

Journal of Cancer Research and Clinical Oncology · 07.10.2025 · 151 (11)

DOI: 10.1007/s00432-025-06335-2 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Cancer Research and Clinical Oncology, online erschienen am 07.10.2025. Verfasst von Wen-Kuan Huang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan, Taiwan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Benzamides, Phenylthiohydantoin, Androstenes. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: The real-world effectiveness and safety of abiraterone or enzalutamide in the Asian population with metastatic castration-resistant prostate cancer (mCRPC) remains unclear. METHODS: Using the Taiwan National Health Insurance Research Database, we identified a cohort of 3056 patients diagnosed with mCRPC receiving abiraterone or enzalutamide from January 1, 2017 through April 30, 2020, followed until December 31, 2021. We applied inverse probability of treatment weighting (IPTW) to balance the treatment groups and compare outcomes between the two treatment groups. Effectiveness outcomes included all-cause death, prostate cancer-related death, and treatment failure. Safety outcomes included major adverse CV events (MACE), fractures, and venous thromboembolism (VTE). RESULTS: Enzalutamide use was associated with superior overall survival (hazard ratio 0.88, 95% confidence interval [CI] 0.82-0.96) compared with abiraterone use, which was majorly contributed from pre-docetaxel use (HR 0.89, 95% CI 0.81-0.98) but not post-docetaxel use (HR = 0.93, 95% CI 0.80-1.07). The median overall survival of pre-docetaxel abiraterone and enzalutamide was 36.1 and 39.9 months, respectively. In contrast, the median overall survival of post-docetaxel abiraterone and enzalutamide was 22.5 and 24.2 months, respectively. In terms of safety outcomes, enzalutamide use was significantly associated with lower VTE events compared with abiraterone use, but there was no difference in MACE or fracture risk between enzalutamide and abiraterone. CONCLUSIONS: We demonstrated the survival of enzalutamide and abiraterone use in Taiwanese patients with mCRPC is consistent with pivotal trials. The higher VTE risk with abiraterone use should be monitored.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantBenzamidesPhenylthiohydantoinAndrostenesHumansMaleNitrilesTaiwanAgedMiddle AgedRegistriesCohort StudiesAged, 80 and overTreatment Outcome

Stichwörter der Autor:innen

AbirateroneCV safetyEnzalutamideMetastatic castration-resistant prostate cancerSurvival analysis

Substanzen

enzalutamideNitrilesBenzamidesabirateronePhenylthiohydantoinAndrostenes

Autor:innen und Institutionen

  • Division of Hematology/Oncology, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan, Taiwan.
  • Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan, 333, Taiwan.
  • Division of Urology, Department of Surgery, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan, 333, Taiwan. jacobpang@cgmh.org.tw.
  • Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan, 333, Taiwan. dongyi70@gmail.com.

Zitieren

APA

Huang, W. K., Su, P. J., Chen, C. C., Chang, C. F., Yu, S. M., Hsieh, M. J., Tsai, M. L., Chen, T. H., Chu, P. H., Hsieh, I. C., Pang, S. T., & Chen, D. Y. (2025). Comparative effectiveness and safety of enzalutamide versus abiraterone in patients with metastatic castration-resistant prostate cancer: a nationwide registry-based cohort study from Taiwan. Journal of Cancer Research and Clinical Oncology, 151(11). https://doi.org/10.1007/s00432-025-06335-2

Vancouver

Huang WK, Su PJ, Chen CC, Chang CF, Yu SM, Hsieh MJ, et al. Comparative effectiveness and safety of enzalutamide versus abiraterone in patients with metastatic castration-resistant prostate cancer: a nationwide registry-based cohort study from Taiwan. Journal of Cancer Research and Clinical Oncology. 2025;151(11). doi:10.1007/s00432-025-06335-2

BibTeX
@article{Huang2025,
  author = {Huang, Wen-Kuan and Su, Po-Jung and Chen, Chun-Chi and Chang, Ching-Fu and Yu, Shao-Ming and Hsieh, Ming-Jer and Tsai, Ming-Lung and Chen, Tien-Hsing and Chu, Pao-Hsien and Hsieh, I-Chang and Pang, See-Tong and Chen, Dong-Yi},
  title = {Comparative effectiveness and safety of enzalutamide versus abiraterone in patients with metastatic castration-resistant prostate cancer: a nationwide registry-based cohort study from Taiwan},
  journal = {Journal of Cancer Research and Clinical Oncology},
  year = {2025},
  volume = {151},
  number = {11},
  doi = {10.1007/s00432-025-06335-2}
}
Kostenlos starten →